Global Emphysema Drug Market - Industry Trends - Forecast to 2026

  • Pharmaceutical
  • Upcoming Reports
  • Jun 2019
  • Global
  • 350 Pages
  • No of Tables: 60
  • No of Figures: 220
Global Emphysema Drug Market By Type (Paraceptal, Pentrilobular, Panlobular ), Mechanism of Action Type (Bronchodilators, Beta-agonists, Anticholinergics, Corticosteroids, Phosphodiesterase -4 Inhibitors and Mucolytics), Stages Type (Very mild or Stage 1: FEV1 is about 80.0% of normal, Moderate or Stage 2: FEV1 is between 50.0% and 80.0% of normal, Severe or Stage 3: FEV1 is between 30.0% and 50.0% of normal, Very severe or Stage 4: FEV1 is lower than in Stage 3, or the same as Stage 3 but with low blood oxygen levels), Therapy Type (Oxygen Therapy, Protein Therapy), Drug Type (Aclidinium, Formoterol, Salmeterol, Levalbuterol, Ipratropium, Olodaterol,Ffluticasone, Budesonide, Prednisolone), Route of Administration (Oral, Inhaled, Intravenous and others), Surgery Type (Lung Volume Reduction Surgery, Lung Transplant Surgery), Device Type (Inhalers, Pressurized Metered-Dose Inhalers (mdis) ,Dry-Powder Inhalers (dpis), Nebulizers, Soft Mist Inhalers), End- Users (Hospitals, Homecare, Specialty Clinics, Others),Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) - Industry Trends & Forecast to 2026

Market Analysis: Global Emphysema Drug Market

Global emphysema drug market is rising substantially in the forecast period of 2019-2026, this rise in market value can be attributed to the increasing awareness and concerns regarding the health of patients, high smoking prevalence, growing medical spending, increasing global healthcare expenditure and technological advancements in pharmaceuticals research.

Market Definition: Global Emphysema Drug Market

Emphysema is a long-term, progressive disease of lungs often called as obstructive lung disease which involves shortness of breath due to damaging and stretching of the alveolar sacs which are involved in exchange of gases. The patient of emphysema experiences frequent lung infections, excess mucous, shortness of breath, fatigue, reduced appetite and weight loss, anxiety, depression, sleep problems.

According to the World Health Organization, emphysema affects nearly 210.00mm people which are attributed to the increasing population in urban areas across the globe and growing number of tobacco smokers.

Market Drivers

  • Growing prevalence of emphysema and associated diseases
  • Rising patient population and increase in availability of novel combination therapy drugs
  • Increasing awareness regarding emphysema
  • High smoking prevalence
  • Growing global healthcare expenditure and technological advancements in pharmaceuticals research

Market Restraints

  • Lack of awareness among the patient and physician about emphysema treatment
  • Patent expiry from many companies and introduction of generic drugs is expected to restrain the growth of the market
  • Effective treatment is either unavailable or unaffordable

Segmentation: Global Emphysema Drug Market

By Type

  • Paraceptal
  • Centrilobular
  • Panlobular

By Mechanism of Action Type

  • Bronchodilators
  • Beta-Agonists
  • Anticholinergics
  • Corticosteroids
  • Phosphodiesterase -4 Inhibitors
  • Mucolytics
  • Others

Stages Type

  • Very mild or Stage 1: FEV1 is about 80 percent of normal
  • Moderate or Stage 2: FEV1 is between 50 and 80 percent of normal
  • Severe or Stage 3: FEV1 is between 30 and 50 percent of normal
  • Very severe or Stage 4: FEV1 is lower than in Stage 3, or the same as Stage 3 but with low blood oxygen levels

Surgery Type

  • Lung Volume Reduction Surgery
  • Lung Transplant Surgery

By Drug Type

  • Aclidinium
  • Formoterol
  • Salmeterol
  • Levalbuterol
  • Ipratropium
  • Olodaterol
  • Fluticasone
  • Budesonide
  • Prednisolone
  • Others

By Treatment

  • Oxygen Therapy
  • Protein Therapy
  • Surgery

By Route of Administration

  • Oral
  • Inhaled
  • Intravenous
  • Others

By Device Type

  • Inhalers
  • Pressurized Metered-Dose Inhalers (MDIs)
  • Dry-Powder Inhalers (DPIs)
  • Nebulizers
  • Soft Mist Inhalers

By End Users

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Surgical centers
  • Others

By Geography

  • North America

    • U.S.
    • Canada
    • Mexico

  • South America

    • Brazil
    • Argentina
    • Rest of South America

  • Europe

    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Turkey
    • Belgium
    • Netherlands
    • Switzerland
    • Rest of Europe

  • Asia-Pacific

    • Japan
    • China
    • South Korea
    • India
    • Australia
    • Singapore
    • Thailand
    • Malaysia
    • Indonesia
    • Philippines
    • Rest of Asia Pacific

  • Middle East & Africa

    • South Africa
    • Egypt
    • Saudi Arabia
    • United Arab Emirates
    • Israel
    • Rest of Middle East & Africa

Key Developments in the Market

  • In June 2018, Pulmonx developed a new device intended to treat breathing difficulty associated with severe emphysema has been approved by the FDA. The device, Pulmonx’s Zephyr Endobronchial Valve (Zephyr Valve) is a less invasive treatment than options currently available to patients
  • In June 2016, Shire and Kamada Pharmaceuticals received approval from the FDA for the expanded label for self-infusion of the Glassia, an alpha-1 Proteinase Inhibitor, developed for the treatment of emphysema due to severe Alpha-1 Antitrypsin (AAT) deficiency that can be self-infused at home after appropriate training

Competitive Analysis: Global Emphysema Drug Market

Global emphysema drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of emphysema drug market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Key Market Players: Global Emphysema Drug Market

Few of the major competitors currently working in the global emphysema drug market are Intrexon, Pulmonx, Halozyme, Inc, Mariposa Health, BTG International Ltd, Icure, Pfizer Inc, Kamada Pharmaceuticals, Olympus Corporation, Spiration, Inc, Lifetech Scientific, CSL, F. Hoffmann-La Roche Ltd, Angion Biomedica corp, Prometic Life Sciences Inc, GlaxoSmithKline plc, Grifols, S.A, AstraZeneca, United Therapeutics Corporation, Sunovion Pharmaceuticals Inc and others.

Research Methodology: Global Emphysema Drug Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Primary Respondents

Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.

Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Reasons to Purchase this Report

  • Current and future of global emphysema drug market outlook in the developed and emerging markets
  • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
  • Regions/Countries that are expected to witness the fastest growth rates during the forecast period
  • The latest developments, market shares, and strategies that are employed by the major market players

Customization of the Report:

  • All segmentation provided above in this report is represented at country level
  • All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)


Please fill in the below form for detailed Table of Content

Please fill in the below form for detailed List of Table

Please fill in the below form for detailed List of Figure

Please fill in the below form for detailed Inquire Before Buying

Choose License Type
  • $5400.00
  • $4200.00